

Insys Therapeutics, Inc.
Form 4
March 18, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Babich Michael L

(Last) (First) (Middle)

444 SOUTH ELLIS STREET

(Street)

CHANDLER, AZ 85224

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Insys Therapeutics, Inc. [INSY]

3. Date of Earliest Transaction
(Month/Day/Year)
03/16/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

President and CEO

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2015		M	30,000	A \$ 3.25	202,752 ⁽¹⁾	D
Common Stock	03/16/2015		M	45,755	A \$ 2.36	248,507	D
Common Stock	03/16/2015		M	1,845	A \$ 7.26	250,352	D
Common Stock	03/16/2015		S	8,224	D \$ 57.91 ⁽²⁾	242,128	D
Common Stock	03/16/2015		S	23,500	D \$ 59.07	218,628	D

Edgar Filing: Insys Therapeutics, Inc. - Form 4

Common Stock	03/16/2015	S	13,546	D	(3) \$ 59.71	205,082	D
					(4)		
Common Stock	03/16/2015	S	2,330	D	\$ 60.62	202,752	D
					(5)		
Common Stock	03/17/2015	M	27,400	A	\$ 7.26	230,152	D
Common Stock	03/17/2015	S	12,500	D	\$ 57.21	217,652	D
					(6)		
Common Stock	03/17/2015	S	13,300	D	\$ 58.12	204,352	D
					(7)		
Common Stock	03/17/2015	S	1,600	D	\$ 58.95	202,752	D
					(8)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 3.25	03/16/2015		M	30,000	(9) 03/27/2021	Common Stock	30,000
Stock Option (right to buy)	\$ 2.36	03/16/2015		M	45,755	(10) 12/26/2022	Common Stock	45,755

Stock Option (right to buy)	\$ 7.26 ⁽¹¹⁾	03/16/2015	M	1,845	⁽¹²⁾	05/13/2023	Common Stock	1,845
Stock Option (right to buy)	\$ 7.26	03/16/2015	M	27,400	⁽¹²⁾	05/13/2023	Common Stock	27,400

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Babich Michael L 444 SOUTH ELLIS STREET CHANDLER, AZ 85224	X		President and CEO	

Signatures

/s/ Michael
Babich 03/18/2015

 Signature of
Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 457 shares acquired by the Reporting Person on December 10, 2014 pursuant to the Issuer's ESPP.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$57.44 to \$58.41, inclusive.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.46 to \$59.45, inclusive.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$59.46 to \$60.41, inclusive.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$60.46 to \$60.86, inclusive.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.67 to \$57.66, inclusive.
- (7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$57.70 to \$58.70, inclusive.
- (8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$58.73 to \$59.20, inclusive.
- (9) The option vests in 48 equal monthly installments and will be fully vested and exercisable on March 28, 2015.
- (10) The option vests in 36 equal monthly installments and will be fully vested and exercisable on December 27, 2015.
- (11) The exercise price reflects a 3-for-2 stock split effected by the Issuer on March 28, 2014
- (12) The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 14, 2017.

Edgar Filing: Insys Therapeutics, Inc. - Form 4

- (13) On March 28, 2014, the Issuer effected a 3-for-2 stock split, resulting in the reporting person's ownership of 125,000 additional options

Remarks:

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The r

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.